RPRX
Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology · US
$67.30
−0.40%Forward multiples
Based on analyst estimates
- P/E forward
- 13.22x
- P/E 2026E
- 12.77x
- P/E 2027E
- 11.70x
- P/E 2028E
- 10.40x
- P/S forward
- 8.42x
Trailing multiples
Trailing twelve months
- P/E TTM
- 39.81x
- PEG TTM
- 0.20x
- Price / book
- 4.38x
- Price / sales
- 11.45x
- Price / cash flow
- 10.12x
Enterprise value
- Enterprise value
- $41.0B
- EV / sales
- 15.66x
- EV / EBITDA
- 26.47x
- EV / EBIT
- 26.18x
- Market cap
- $30.0B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Sep 1, 2026